Tasly Pharmaceutical Group Co Ltd

Common Name

Tasly Pharmaceutical Group

Country

China (Mainland)

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Employees

10,958

Ticker

600535

Exchange

SHANGHAI STOCK EXCHANGE

Website

www.taslypharma.com

Description

Tasly Pharmaceutical Group Co., Ltd. is a prominent entity in the pharmaceutical industry, primarily involved in the research, development, production, and marketing of modern Traditional Chinese Medi... Show more

Financial Statements of Tasly Pharmaceutical Group

Below are the financial statements of Tasly Pharmaceutical Group, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.

Income Statement (as reported) Balance Sheet (as reported)

All figures in millions of CNY	2024	2023
Total operating revenue	8,498.14^a	8,674.01^a
Operating revenue	8,498.14^a	8,674.01^a
Total operating costs	-7,056.79^a	-7,232.91^a
Operating costs	-2,792.25^a	-2,880.1^a
Taxes and surcharges	-125.95^a	-128.7^a
Selling expenses	-2,988.3^a	-2,983.53^a
Administrative expenses	-345.4^a	-342.37^a
Research and development expenses	-830.07^a	-917.27^a
Finance costs	-25.18^a	-19.06^a
Interest expense	-61.28^a	-82.52^a
Interest income	91.05^a	107.55^a
Other income	78.3^a	82.75^a
Investment income (loss indicated by '-')	-84.4^a	-110.92^a
Investment income from associates and joint ventures	-106.21^a	-130.04^a
Gains on derecognition of financial assets measured at amortized cost	0.05^a	0^a
Fair value gains (losses)	-129.05^a	-171.88^a
Credit impairment losses (loss indicated by '-')	-0.62^a	-8.19^a
Asset impairment losses (loss indicated by '-')	-231.77^a	-5.12^a
Gains on disposal of assets (loss indicated by '-')	2.11^a	0.15^a
Operating profit (loss)	1,075.92^a	1,227.88^a
Non-operating income	14.48^a	3.06^a
Non-operating expenses	-21.72^a	-9.84^a
Total profit (loss)	1,068.69^a	1,221.1^a
Income tax expense	-209.63^a	-204.46^a
Net profit (loss)	859.06^a	1,016.64^a
Net profit (loss) from continuing operations	859.06^a	1,016.64^a
Net profit attributable to owners of the parent	955.59^a	1,071.07^a
Profit or loss attributable to non-controlling interests	-96.53^a	-54.43^a

Verified Sources Behind Tasly Pharmaceutical Group’s Financial Fundamentals Data

Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Tasly Pharmaceutical Group’s data sources below and access millions more through our Disclosure Search.

a. Tasly Pharmaceutical Group's Annual Report 2024

Trace every data point back to Tasly Pharmaceutical Group’s disclosures

Sign up for Tracenable and access millions of corporate disclosures, including annual reports and sustainability filings from global companies, completely free of charge.

Real-Time & Standardized Financials

Access Standardized Financial Statements within Minutes of Disclosure

At Tracenable, we're exploring the launch of real-time standardized financial datafeeds and APIs covering global equities. Unlike limited and inconsistent XBRL parsing, our approach aims to deliver clean, comparable, and fully traceable data seconds after publication.

Could this solution support your investment or analytical workflows?

Explore Peer Companies

Welcome Back to Tracenable

Sign in to your account

Tasly Pharmaceutical Group Co Ltd

Financial Statements of Tasly Pharmaceutical Group

Verified Sources Behind Tasly Pharmaceutical Group’s Financial Fundamentals Data

Access Standardized Financial Statements within Minutes of Disclosure

Explore Peer Companies

Joincare Pharmaceutical Group Industry Co Ltd

Hansoh Pharmaceutical Group Company Ltd

WuXi Biologics (Cayman) Inc

Pharmaron Beijing Co Ltd

Genscript Biotech Corp

Zai Lab Ltd